Sam Lockhart
@lockhartbrains
Followers
832
Following
152
Media
26
Statuses
229
Imaging Biomarker researcher, Cognitive Neuroscientist, Husband/Father, and, you know, fan of stuff. Tweets are my own.
Winston-Salem, NC
Joined July 2019
The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) revolutionizes in vivo characterization of mixed pathologies. Learn about the creation of an unprecedented publicly available imaging–plasma–neuropath dataset in A&D: https://t.co/l3D3V7ghNm
#AlzResearch
alz-journals.onlinelibrary.wiley.com
The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer's Disease...
0
5
7
Meet Dr Samuel N. Lockhart, the moderator for the upcoming AD/PD™ Journal Club. Join him and his fellow expert speakers by securing your spot today! 📅 Date: 4th February 2025 ⏲️ Time: 16:00 CET Register Now: https://t.co/sduGydEGMZ 👈 Dr. Samuel Lockhart is a Neuroscientist
0
1
5
Bateman et al, analyzing transcriptional data during the pandemic, found eudaimonic well-being inversely associated with CTRA gene expression (response to adverse social conditions) in participants with normal cognition & MCI. @RenegadeSynapse @WakeADC
alz-journals.onlinelibrary.wiley.com
INTRODUCTION Adverse psychosocial exposure is associated with increased pro-inflammatory gene expression and reduced type-1 interferon gene expression known as the conserved transcriptional respons...
0
0
4
🔊 Join us for the next AD/PD™ Journal Club. We will be exploring the intricate nuances of #biomarker discovery and their implications for early diagnosis. Expert Panel: Prof. Lisa Zukowski and Prof. Samuel Lockhart 📅 Date: Wednesday, October 2nd ⏲️ Time: 16:00 CEST Register
0
1
4
Attending #SNMMI 2024 Therapeutics in Bethesda, MD? Join us on Wed. 9/18 at the Streamlining Collaborations: Study Startups Workshop Session 3 at 4:15pm for Paolo Zanotti Fregonara’s session “Unique Challenges for Radiopharmaceutical Therapy (RPT) Trials - iCRO Perspective.”
0
1
1
Members of the ADACC Network, Drs. Hughes, Dage, Mielke, Craft, and Lockhart and other collaborators examined the use of neuroimaging-derived biomarkers of ADRD and the impact of health-related comorbidities. 🔖Read about their finding: https://t.co/Po61ZDBTLi….
alz-journals.onlinelibrary.wiley.com
INTRODUCTION We evaluated associations between plasma and neuroimaging-derived biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities. METHODS We ex...
0
1
0
Congrats to @marcdrudolph for leading this fascinating project!
@marcdrudolph led an amazing analysis of associations among plasma, MRI, and amyloid PET biomarkers of ADRD and the impact health-related comorbidities have on associations in @WakeADC ppts https://t.co/xtwERUbsz8
@lockhartbrains @RenegadeSynapse @NeuroNene @dage_jeff @fishTMH
0
0
4
3 new pubs out of our group!
3 new early-career @WFADRC pubs: @sudkrish w/a case on prion disease in mixed dem https://t.co/B5onOoc8Vw;
@TugcesTweeting validated a remote/UDSv4-friendly PACC; https://t.co/se1wqmJcLT;
@brettmfrye examined how Med diet in NHP may be neuroprotective!
1
1
8
Normal tau in Alzheimer's patients is not just explained by earlier disease stage -- it is linked to cardiovascular risk and older age, and alpha-synuclein copathology drives lower cognition. Thanks to @birtutamtuz @tessamharrison, ADNI, and many others https://t.co/fwOG47KFjt
2
27
87
The @WakeADC will participate in the 2023 Walk to End Alzheimer’s (10am Sat. 11/4, Truist Stadium in Winston-Salem), as part of the Sticht Center for Healthy Aging and Alzheimer’s Prevention team. Please consider joining us, or donating at https://t.co/Cn4gahnG7T. Thank you!
0
1
2
Dr. Miranda Orr at @WakeADC led a national phase 1 study ( https://t.co/ymQcGLP06s) to target senescent “zombie” cells, in work published in Nature Medicine ( https://t.co/74Zi9IcYyj). Her pioneering research focuses on how changes that occur with aging influence AD risk! Congrats!
nature.com
Nature Medicine - The first feasibility study of orally delivered senolytic therapy in Alzheimer’s disease reports favorable safety data and penetrance of dasatinib into the brain with a...
0
1
6
Are you attending AIC? (You should!) Are you a trainee? Don't miss the opportunity to take part in the mentoring session and to discuss with the expert of your choice over lunch! Fill this form by June 12 to register: https://t.co/w2Y7W0De1p
2
14
31
Interested in using WF ADRC resources for your project? Click on https://t.co/LJHFDgfr2k to find out what resources are available for your studies at the WF ADRC!
0
3
4
@TugcesTweeting did a fantastic job discussing her work at @WakeADC on validating a telecognitive variation on the PACC!
1
3
11
@susan_landau presenting on the U.S. POINTER Imaging study @HAIconference! This is an imaging ancillary to #USPOINTER, a multidomain lifestyle intervention trial led by researchers at @WakeADC @WakeGeriatrics. Congratulations, Dr. Landau!
0
1
4
I forgot to list on my biosketch all the effort I have to spend on updating and sending my biosketch
1
0
17
Trey Bateman @RenegadeSynapse presents his work on COVID, stress and loneliness at the @WakeADC Winter Full Investigators Meeting at @wakeforestmed! He may look alone up there, but he is not lonely.
0
1
4
Miranda Orr @Orr_Lab continues the @WakeADC Winter Full Investigators Meeting talking about the STOMP-AD senolytic therapy trial at @wakeforestmed!
0
1
4